People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other Technology, Other Health Care, Biotechnology, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Quantenna Communications Inc | — | Other Technology | Series C | $208.2M | $1.1B | 2009 |
| TileDB, Inc. | — | Other Technology | Series B | $52.1M | $326.9M | 2023 |
| R2 Semiconductor Inc | — | Other Technology | Series A | $42.2M | $194.2M | 2010 |
| Elisity, Inc. | — | Other Technology | Series B | $39.1M | $321.0M | 2024 |
| Cell Works Group Inc | — | Other Technology | Series B | $33.0M | $471.4M | 2012 |
| pulseData, Inc. | — | Other Health Care | Series B | $19.7M | $291.5M | 2021 |
| Novoron Bioscience, Inc. | — | Biotechnology | Series A | $15.2M | $135.2M | 2021 |
| OpenDNS, Inc. | — | Other Technology | Series A | $13.8M | $257.1M | 2010 |
| Arch Systems Inc. | — | Software / Tech | Series A | $12.0M | $37.1M | 2023 |
| FYR Diagnostics, Inc. | — | Biotechnology | Series A | $8.0M | $40.2M | 2024 |
MICHAEL GOGUEN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MICHAEL GOGUEN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| FAHRI DINER | 2 | 7 |
| ROBERT SCHWARTZ | 1 | 21 |
| Satya Patel | 1 | 20 |
| Spencer Tall | 1 | 12 |
| Brian Long | 1 | 11 |
| David Ulevitch | 1 | 11 |
| ABHISHEK SHARMA | 1 | 10 |
| Jean-Francois Clavier | 1 | 10 |
| Stefan Dyckerhoff | 1 | 8 |
| Yatin Mundkur | 1 | 7 |
| David Strohm | 1 | 6 |
| Brian Thompson | 1 | 6 |
| Steven Goldberg | 1 | 5 |
| John Scull | 1 | 5 |
| Drew Lanza | 1 | 4 |
| Dmitry Akhanov | 1 | 4 |
| DAVID FRENCH | 1 | 4 |
| JOHN MARREN | 1 | 4 |
| David Lawrence | 1 | 4 |
| DAVID FISHER | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.